DEMAPHARMA
ActiveSummary
DEMAPHARMA has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €385,336 and a net result of €17,290. Equity is growing by about 11% per year across the filed financial years. Its solvency ranks better than 72% of 12,724 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Directors
Directors
2 directors, last change in 2023
Marchal Sylvie
CurrentDirector (not named in the articles) · since 22-06-2023
MICHEL Denise
CurrentAdministrateur subsidiaire · since 22-06-2023
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ.
See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
1 of this company's 2 Belgian Official Gazette deeds has not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.
Mandate history
2 people since 2023, 2 in office
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| Marchal Sylvie |
|
| MICHEL Denise |
|
Owners and capital
Capital and shareholders
Capital over the years
- 22-06-2023 Converted to unavailable equity · €18,600